ArticleJournal of neuro-oncology2019
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.Acta neuropathologica communications · 2023Pooled it
- The superior prognostic role of pRB1 over p16 immunohistochemistry as a biomarker in meningiomas.Acta neuropathologica communications · 2026Article
- Utility of digital PCR for detecting TERT promoter mutations and CDKN2A homozygous deletion in meningioma.Brain tumor pathology · 2026Article
- Longitudinal Evolution and Cellular Plasticity in Meningioma: Insights From Single-Cell Transcriptomics.Brain tumor research and treatment · 2026Review
- Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity.Nature communications · 2025Article
- Molecular biomarkers in meningioma (Review).Biomedical reports · 2025Review
- Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.Journal of neuropathology and experimental neurology · 2024Article
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.Neuro-oncology practice · 2024Article
- Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution.Nature genetics · 2024Article
- Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome.Biomedicines · 2023Article
- Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.Acta neuropathologica · 2023Article
- Meningioma Grading beyond Histopathology: Relevance of Epigenetic and Genetic Features to Predict Clinical Outcome.Cancers · 2023Review
- Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution.Research square · 2023Article
- Surgical strategies for intracranial meningioma in the molecular era.Journal of neuro-oncology · 2023Review
- Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.Acta neuropathologica · 2023Article
- Intraoperative Flow Cytometry for the Evaluation of Meningioma Grade.Current oncology (Toronto, Ont.) · 2023Article
- Brain Invasion and Trends in Molecular Research on Meningioma.Brain tumor research and treatment · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAssessment of the risk of recurrence is essential to determine the therapeutic strategy of meningioma treatment. Many relapsing or aggressive meningiomas show elevated mitotic and/or Ki67 indices, reflecting cell cycle deregulation. As CDKN2A is a key tumor suppressor gene involved in cell cycle control, we investigated whether CDKN2A alterations may be involved in tumor recurrence.
methodsWe carried out a comparative analysis of 17 recurrent and 13 non-recurrent meningiomas. CDKN2A single nucleotide variations (SNVs), deletions, methylation status of the promotor, and p16 expression were investigated. Results were correlated with the recurrent or non-recurrent status and clinicopathological data.
resultsWe identified a CDKN2A SNV (NM_000077, exon2, c.G442A, p.Ala148Thr) in five meningiomas that was significantly associated with recurrence (p = 0.03). This mutation, confirmed by Sanger sequencing and referenced in the COSMIC database in various cancers, has not been reported in meningioma. The presence of one of the three following CDKN2A alterations-p.(Ala148Thr) mutation, whole homozygous or heterozygous gene loss, or promotor methylation > 8%-was observed in 13 of the 17 relapsing meningiomas and was strongly associated with recurrence (p < 0.0001) and a Ki67 labeling index > 7% (p = 0.004).
conclusionWe report an undescribed p.(Ala148Thr) CDKN2A mutation in meningioma that was only present in relapsing tumors. In our series, CDKN2A gene alterations were only found in recurrent meningiomas. However, our results need to be evaluated on a larger series to ensure that these CDKN2A alterations can be used as biomarkers of recurrence in meningioma.
Indexed as
Identifiers
31729637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.